Vaxart, a clinical-stage biotechnology company, appointed Edward Berg as the company’s first in-house general counsel.
Berg has practiced law for more than 30 years and has represented Fortune 500 and mid-cap companies in biotechnology, pharmaceuticals, and life sciences. He joins Vaxart from BioMarin Pharmaceutical, where he served as vice president, deputy general counsel since 2018.
At BioMarin Pharmaceutical, Berg and his legal team counseled on product launches and supported internal and external collaborative efforts that led to the development of an innovative early pipeline in the competitive gene therapy space.
Berg’s previous roles include deputy general counsel, pharmaceutical operations for Sanofi-Aventis U.S. and Sanofi NA Pharmaceuticals and senior corporate counsel, research and development at Bristol-Myers Squibb. He began his career in healthcare as senior attorney/associate counsel for Merck & Co.